HLVX merger: director cashed out 59,224 shares; CVRs issued
Rhea-AI Filing Summary
Jeryl Hilleman, a director of HilleVax, Inc. (HLVX), disposed of 59,224 shares of Common Stock as part of a change-in-control transaction that closed on September 17, 2025. Under an Agreement and Plan of Merger, holders received $1.95 in cash per share plus one contingent value right (CVR) per share that may pay additional contingent cash proceeds as described in the CVR agreement. After the reported transaction Hilleman reports 0 shares beneficially owned. The filing also states that outstanding restricted stock units vested and were canceled immediately prior to the merger, with holders receiving cash equal to $1.95 times the underlying shares and one CVR per underlying share.
Positive
- Shareholders received immediate cash consideration of $1.95 per share, providing certainty of value at the time of the transaction
- Holders received CVRs that preserve potential contingent upside beyond the cash payment
Negative
- Reporting person now holds 0 shares, indicating insiders no longer have direct equity exposure post-transaction
- Public float reduced as the issuer became a wholly owned subsidiary, which may limit future liquidity for remaining public holders
Insights
TL;DR: Insider holdings were eliminated due to a completed merger, with RSUs cashed out and CVRs issued.
The reported disposition is administrative and tied to a completed acquisition rather than an open-market sale. The structure—cash paid per share plus CVRs—means former equity holders retain contingent upside via CVRs while losing direct stock ownership and voting rights. Cancellation and vesting of RSUs for cash and CVRs follows common merger mechanics; material governance change is the company becoming a wholly owned subsidiary of the acquiror.
TL;DR: The transaction removed a director's public equity stake and replaces it with fixed cash and contingent consideration.
From an investor-impact perspective, the transaction is material as it extinguishes public float and converts equity into $1.95 cash per share plus CVRs, potentially affecting liquidity and remaining public shareholders (if any). The reported 59,224-share disposition reduces the reporting person's direct exposure to any future public-market performance, but retains contingent value through CVRs for possible additional cash.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| U | Common Stock | 59,224 | $0.00 | -- |
Footnotes (1)
- In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.
